Dare Bioscience (DARE) Reports Q3 Loss of $0.23

Dare Bioscience (NASDAQ: DARE) reported Q3 EPS of ($0.23), versus ($0.33) reported last year.

“We are actively enrolling couples in our postcoital test clinical trial of Ovaprene®, our non-hormonal monthly contraceptive, and are preparing to commence the Phase2b program of Sildenafil Cream, 3.6%, our candidate for the treatment of female sexual arousal disorder. We are also advancing our development portfolio of other product candidates that we believe have the potential to deliver a first-in-category product addressing a persistent unmet need in women’s reproductive health, such as our vaginal ring technologies for hormone replacement and pregnancy maintenance and our vaginal tamoxifen for vulvar and vaginal atrophy in women with hormone receptor positive breast cancer,” said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré. “Our 2018 third quarter results were in line with our expectations for advancing our novel portfolio of clinical candidates in women’s health.”

For earnings history and earnings-related data on Dare Bioscience (DARE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Playboy to buy back 16.6M shares from Fortress at $1.05 each
• Ciena names new supply chain and product technology chiefs